Scholarlink

Background <p>Although the addition of neoadjuvant immune checkpoint blockade to chemotherapy has improved patient outcome in early triple‑negative breast cancer (TNBC), some patients continue to have poor disease outcomes.</p> Methods <p>To characterise neoadjuvant chemotherapy (NAC) resistant cell populations that persist post-NAC, we created a high-resolution single-cell atlas of 129,433 cells from fourteen TNBC patient-derived xenograft (PDX) models with residual disease post-NAC. We identified transcriptionally distinct cancer subpopulations or cell states using unsupervised clustering and characterised‑ their regulatory network as well as clinical associations with treatment response, metastatic progression and survival. Findings were validated using multiple independent TNBC cohorts.</p> Results <p>Four major transcriptionally distinct cancer cell states were identified that were shared across the PDX models. These cell states were characterised by enrichment of developmental, hypoxia, interferon signalling, chromosomal instability, and DNA-damage pathways. Hypoxia and interferon signalling cell states shared transcriptional features of drug-tolerant persister cells. Hypoxia cell states contained both cycling and non-cycling cells and were not associated with mutation status. Extensive validation in TNBC patient cohorts confirmed that dysregulated pathways enriched in residual disease were pre-existing in chemotherapy-naïve patients, maintained in distant metastases and were both prognostic and predictive of treatment response. <i>In vitro</i> functional validation highlighted that inhibition of the lysine demethylase KDM5B suppressed the emergence of drug‑tolerant persister cells.</p> Conclusions <p>Neoadjuvant therapy selects for epigenetically regulated, hypoxia-related cycling and non-cycling drug‑tolerant persister cells in TNBC. These cell states are maintained in metastatic disease and are prognostic/predictive of therapy response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Yu Zhang,
  • Fatemeh Ahmadi Moughari,
  • Ioanna Mavrommati,
  • Nora J. Doleschall,
  • Kate Moore,
  • Gareth Muirhead,
  • Ram Rajaram Srinivasan,
  • Ping Gong,
  • Jonathan T. Lei,
  • Amy Fleming,
  • Hwei Minn Khoo,
  • Naomi Guppy,
  • Gabrielle Elshtein,
  • Mohammed Inayatullah,
  • Vijay K. Tiwari,
  • Lacey E. Dobrolecki,
  • Michael T. Lewis,
  • Syed Haider,
  • Rachael Natrajan

摘要

Background

Although the addition of neoadjuvant immune checkpoint blockade to chemotherapy has improved patient outcome in early triple‑negative breast cancer (TNBC), some patients continue to have poor disease outcomes.

Methods

To characterise neoadjuvant chemotherapy (NAC) resistant cell populations that persist post-NAC, we created a high-resolution single-cell atlas of 129,433 cells from fourteen TNBC patient-derived xenograft (PDX) models with residual disease post-NAC. We identified transcriptionally distinct cancer subpopulations or cell states using unsupervised clustering and characterised‑ their regulatory network as well as clinical associations with treatment response, metastatic progression and survival. Findings were validated using multiple independent TNBC cohorts.

Results

Four major transcriptionally distinct cancer cell states were identified that were shared across the PDX models. These cell states were characterised by enrichment of developmental, hypoxia, interferon signalling, chromosomal instability, and DNA-damage pathways. Hypoxia and interferon signalling cell states shared transcriptional features of drug-tolerant persister cells. Hypoxia cell states contained both cycling and non-cycling cells and were not associated with mutation status. Extensive validation in TNBC patient cohorts confirmed that dysregulated pathways enriched in residual disease were pre-existing in chemotherapy-naïve patients, maintained in distant metastases and were both prognostic and predictive of treatment response. In vitro functional validation highlighted that inhibition of the lysine demethylase KDM5B suppressed the emergence of drug‑tolerant persister cells.

Conclusions

Neoadjuvant therapy selects for epigenetically regulated, hypoxia-related cycling and non-cycling drug‑tolerant persister cells in TNBC. These cell states are maintained in metastatic disease and are prognostic/predictive of therapy response.